Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
Condition: Type 2 Diabetes Mellitus With Complication Interventions: Drug: Canagliflozin; Drug: Pioglitazone Sponsor: First Affiliated Hospital Xi'an Jiaotong University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Actos | Canagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Fatty Liver Disease (FLD) | Hospitals | Invokana | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Research | Urology & Nephrology